Fleming Pharma steps up radiation drug production

Manjula Puthenedam, PhD, | | Health Imaging | Oncology Imaging
Fleming Pharmaceuticals has ramped up production of ThyroShield, a liquid potassium iodide product indicated for thyroid protection in radiation emergencies, to meet increased domestic and international demand.

ThyroShield is an over-the-counter iodide solution which, when taken orally, saturates the thyroid gland so that radioactive iodine cannot be absorbed. The drug is effective for babies and children, who are most at risk during radiation exposure, according to Fenton, Mo.-based Fleming Pharmaceuticals.

The company has qualified a new potassium iodide supplier, established new agreements with vendors to shorten lead times needed to complete orders for ThyroShield package components and identified production line logistics to fulfill any significant new orders for ThyroShield.

Manjula Puthenedam, PhD,

Related Content

High-intensity focused ultrasound could allow prostate cancer patients to avoid surgery
MRI-first approach could allow many to safely forego prostate biopsy
MRI guidance significantly reduces radiotherapy side effects compared to CT
Interventional procedure often as effective as surgery for difficult-to-treat liver cancer
AI tumor volume estimations could improve prostate cancer treatment strategies
MRI could be 'powerful tool' for guiding surgery decisions in patients with rectal cancer

Around the web

Radiology Business
AI can help radiology standardize image exam data labeling

To fully leverage today's radiology IT systems, standardization is a necessity. Steve Rankin, chief strategy officer for Enlitic, explains how artificial intelligence can help.

Radiology Business
The biggest obstacles facing radiology business managers in 2025

RBMA President Peter Moffatt discusses declining reimbursement rates, recruiting challenges and the role of artificial intelligence in transforming the industry.

Cardiovascular Business
New cardiac prevention paradigm explored in TRANSFORM trial using AI and CCTA

Deepak Bhatt, MD, director of the Mount Sinai Fuster Heart Hospital and principal investigator of the TRANSFORM trial, explains an emerging technique for cardiac screening: combining coronary CT angiography with artificial intelligence for plaque analysis to create an approach similar to mammography.